Last updated: September 1, 2026
HEPLISAV-B, the branded form of hepatitis B vaccine (recombinant), adjuvanted, is Dynavax Technologies’ commercial product and the only U.S.-approved adult hepatitis B vaccine using the CpG 1018 adjuvant. Its principal commercial advantage is a two-dose schedule administered over one month, compared with the three-dose schedules used by Engerix-B and Recombivax HB. U.S. sales have expanded as adult vaccination recommendations, employer mandates, diabetes screening, dialysis demand and improved completion rates support conversion from legacy vaccines. [1][2]
The commercial thesis depends on continued market-share gains in adult vaccination rather than large price increases. Key risks are competition from established vaccines, public-sector pricing, supply execution, the absence of a pediatric indication and the potential entry of improved combination or next-generation hepatitis B vaccines.
What is HEPLISAV-B and how does it differ from other hepatitis B vaccines?
HEPLISAV-B is a recombinant hepatitis B surface antigen vaccine containing CpG 1018, an immunostimulatory phosphorothioate oligodeoxynucleotide adjuvant. The FDA approved it in November 2017 for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older. [3]
| Product |
Manufacturer |
Adult schedule |
Adjuvant |
Primary commercial positioning |
| HEPLISAV-B |
Dynavax |
2 doses at 0 and 1 month |
CpG 1018 |
Rapid completion and higher seroprotection |
| Engerix-B |
GSK |
3 doses over 6 months |
Aluminum hydroxide |
Established incumbent |
| Recombivax HB |
Merck |
3 doses over 6 months |
Aluminum hydroxyphosphate sulfate |
Established incumbent |
| PreHevbrio |
VBI Vaccines |
3 doses over 6 months |
No CpG 1018 |
Competitor with three-antigen formulation; U.S. availability has been limited |
HEPLISAV-B’s differentiation is strongest where missed appointments reduce vaccination completion. The product is particularly relevant in occupational-health programs, pharmacies, primary care, diabetes clinics, correctional facilities, dialysis centers and health systems seeking to complete vaccination before patients are lost to follow-up.
How large is the hepatitis B vaccine market?
The global hepatitis B vaccine market is a multibillion-dollar market, but HEPLISAV-B addresses a narrower segment: adults in the United States and selected international markets. Pediatric vaccination remains dominated by national immunization programs and combination pediatric products, where Dynavax does not compete directly with HEPLISAV-B.
The U.S. adult opportunity expanded after the CDC recommended hepatitis B vaccination for all adults aged 19 through 59 years, while adults aged 60 years and older may receive vaccination based on risk or preference. The CDC also maintained risk-based recommendations for health-care workers, people with diabetes, people who inject drugs, people with multiple sex partners, people with chronic liver disease and travelers to endemic areas. [2]
The commercial market has four important demand pools:
- Employer and occupational vaccination, including health-care workers.
- Retail pharmacy and primary-care vaccination.
- High-risk medical populations, including dialysis and diabetes patients.
- Public-sector and institutional purchasing through the CDC, state programs, the Department of Veterans Affairs and the Department of Defense.
HEPLISAV-B is more exposed to private-sector adult vaccination than to pediatric government procurement. That mix generally supports higher realized pricing, but it also creates greater sensitivity to payer coverage, contracting and provider adoption.
What has driven HEPLISAV-B revenue growth?
HEPLISAV-B revenue has been driven by product adoption, schedule convenience and a broadening of adult vaccination policy. Dynavax has reported strong year-over-year growth in net product revenue since commercial launch, with the product becoming the company’s principal recurring revenue source. [1]
Public company filings indicate the following broad trajectory:
| Period |
HEPLISAV-B commercial status |
Financial direction |
| 2017-2018 |
FDA approval and initial launch |
Limited launch revenue; provider education and reimbursement buildout |
| 2019-2020 |
Early adoption |
Gradual uptake, constrained by launch execution and COVID-19 disruption |
| 2021 |
Commercial expansion |
Revenue growth as adult vaccination activity normalized |
| 2022 |
CDC universal adult recommendation in force |
Faster adoption across pharmacies, employers and health systems |
| 2023 |
Broader account penetration |
Product revenue became the dominant recurring revenue stream |
| 2024 onward |
Scale-up phase |
Continued growth depends on conversion of legacy three-dose demand and supply capacity |
Dynavax’s financial profile also changed after HEPLISAV-B became the core product. Earlier results were heavily affected by research spending, commercialization costs and COVID-19-related CpG 1018 collaboration revenue. Those collaboration revenues were episodic and declined after the pandemic vaccine programs diminished. HEPLISAV-B product revenue is more durable, but it has a lower near-term growth rate than a one-time pandemic partnership.
Why does the two-dose schedule matter commercially?
Completion is a major economic variable. A three-dose schedule requires a patient to return at approximately zero, one and six months. HEPLISAV-B requires two visits within one month. Higher completion can improve:
- Vaccine effectiveness at the population level.
- Provider workflow efficiency.
- Employer compliance.
- Revenue per completed vaccination course.
- Patient retention in pharmacy and occupational-health settings.
Clinical studies cited in the prescribing information showed higher seroprotection rates for HEPLISAV-B than Engerix-B in several adult populations, including adults with diabetes and older adults. [3] The commercial benefit is strongest when providers value completion and rapid immunity rather than selecting solely on acquisition price.
What is the financial trajectory for Dynavax and HEPLISAV-B?
HEPLISAV-B has moved Dynavax from a development-stage biotechnology company toward a commercial vaccine company. Product revenue now provides a recurring operating base, while CpG 1018 licensing and collaboration revenue remains a potential but less predictable supplement.
The financial trajectory has four stages:
Launch investment
The first years after FDA approval required sales infrastructure, account contracting, medical education and manufacturing scale-up. This reduced operating leverage and delayed profitability.
Commercial inflection
Growth accelerated as the CDC’s universal adult recommendation expanded the addressable population and as health systems recognized the value of a two-dose schedule. Dynavax’s sales effort increasingly focused on institutional accounts, pharmacy networks and large health systems rather than only specialist prescribers.
Operating leverage
As unit volume increases, fixed commercial and administrative costs should represent a smaller percentage of product revenue. The principal variables are manufacturing cost, inventory reserves, rebates, chargebacks and channel mix. Public filings should be used to distinguish net product revenue from gross billings because government and institutional discounts can materially affect realized price. [1]
Maturity and diversification
The longer-term outcome depends on whether HEPLISAV-B reaches a stable share of the adult U.S. market and whether Dynavax develops additional CpG 1018 partnerships. A mature HEPLISAV-B business could generate predictable cash flow, but it remains concentrated in one marketed product and one main geography.
Dynavax’s revenue quality is therefore improving, but the company remains exposed to product concentration. A manufacturing interruption, safety signal, reimbursement change or competitive schedule innovation could affect the majority of recurring product revenue.
How strong is the competitive position of HEPLISAV-B?
HEPLISAV-B has a meaningful product advantage but not an unassailable market position.
Strengths
- Two-dose adult schedule.
- Strong immunogenicity data in adults, including older adults and people with diabetes.
- Clear differentiation from three-dose incumbent products.
- Established FDA approval and commercial supply history.
- Potential for higher vaccination completion.
- Growing alignment with universal adult hepatitis B vaccination.
Constraints
- U.S. label limited to adults aged 18 years and older.
- No pediatric or adolescent franchise comparable to combination vaccines.
- Higher acquisition cost may limit formulary preference.
- Provider familiarity with Engerix-B and Recombivax HB remains substantial.
- Public-sector tenders can compress net pricing.
- Product concentration exposes Dynavax to execution risk.
- Hepatitis B vaccination demand is preventive and can be deferred when clinical capacity is constrained.
HEPLISAV-B is best positioned as a conversion product in adults rather than as a complete replacement for all hepatitis B vaccine demand.
What patents protect HEPLISAV-B?
HEPLISAV-B protection is based primarily on patents covering CpG 1018, immunostimulatory oligonucleotide compositions, vaccine formulations and methods of inducing an immune response. The relevant estate is more complex than a single active-ingredient patent because the product combines recombinant hepatitis B surface antigen with a proprietary adjuvant.
Publicly associated Dynavax patent families include U.S. patents directed to CpG immunostimulatory sequences and their use in vaccines. Patent scope and expiration depend on the specific family, terminal disclaimers, patent-term adjustment and any regulatory patent-term extension. The FDA Orange Book and Dynavax’s periodic reports should be read together when assessing enforceable U.S. protection. [1][4]
What formulations are protected?
The main technical barriers are likely to involve:
- CpG 1018 composition and sequence claims.
- Combination of CpG 1018 with hepatitis B surface antigen.
- Vaccine dosing and immunization methods.
- Formulation, stability and manufacturing controls.
- Use in populations requiring enhanced immune response.
Formulation and process patents may remain commercially relevant after broader composition claims expire because they can complicate substitution with an equivalent adjuvanted product. Their value depends on claim breadth, prosecution history and whether a rival can design around the protected formulation.
When does HEPLISAV-B lose exclusivity?
There is no single public date that eliminates all HEPLISAV-B exclusivity. Relevant barriers include patent expiry, regulatory exclusivity, manufacturing know-how, FDA approval requirements and the practical difficulty of demonstrating equivalence for a recombinant adjuvanted vaccine.
HEPLISAV-B is not a conventional small-molecule drug with an ANDA pathway. A competing vaccine would generally require its own biologics license application or another applicable FDA pathway. The product also does not create a standard biosimilar opportunity in the same manner as a monoclonal antibody approved under section 351(k) of the Public Health Service Act.
What is the Orange Book and FDA regulatory status of HEPLISAV-B?
HEPLISAV-B is a licensed biological product regulated by the FDA’s Center for Biologics Evaluation and Research. Its regulatory protection should be analyzed through the biologics license, FDA exclusivity rules, patent records and litigation filings rather than through the standard small-molecule generic framework alone. [3][5]
The product’s regulatory characteristics are:
| Regulatory issue |
Status |
| FDA approval |
November 2017 |
| Product type |
Recombinant hepatitis B vaccine with CpG 1018 adjuvant |
| Indication |
Prevention of hepatitis B infection in adults 18 and older |
| Primary approval holder |
Dynavax Technologies |
| Pediatric indication |
Not approved for HEPLISAV-B |
| Biosimilar exposure |
No conventional biosimilar pathway comparable to therapeutic proteins |
| Generic substitution |
No ordinary ANDA substitution pathway |
| Main regulatory risk |
Competing vaccine approval and manufacturing equivalence, not routine generic substitution |
HEPLISAV-B’s regulatory moat is therefore based on a combination of patent rights, clinical differentiation and manufacturing complexity. FDA approval of a competing adult hepatitis B vaccine would not automatically create pharmacy-level substitution in the same way as an approved generic drug.
Are there Paragraph IV challenges or patent litigation affecting HEPLISAV-B?
No major public Paragraph IV challenge has established a conventional generic-entry timetable for HEPLISAV-B. That is consistent with the product’s biologic and vaccine status. A rival would more likely pursue an independent vaccine approval and challenge patents through litigation, inter partes review or a declaratory-judgment action rather than rely on a standard ANDA Paragraph IV filing.
The absence of a public generic challenge does not eliminate competitive risk. Vaccine competitors can enter through:
- A new recombinant vaccine.
- A different adjuvant platform.
- A combination vaccine.
- An improved dosing schedule.
- A public-sector tender strategy.
- A licensing arrangement with an established vaccine manufacturer.
The most credible threat is product competition, not immediate pharmacy substitution.
Which companies are challenging HEPLISAV-B?
The competitive field includes GSK, Merck, VBI Vaccines and manufacturers of regional or combination hepatitis B vaccines.
GSK and Merck have the strongest incumbent positions because Engerix-B and Recombivax HB are established in pediatric, adult, occupational and institutional channels. Their advantages include broad account relationships, supply contracts and familiarity among clinicians.
VBI’s PreHevbrio was designed as an adult hepatitis B competitor with a three-antigen formulation. Its commercial impact has been limited by corporate and supply developments, but the product illustrates the type of differentiated vaccine that could compete with HEPLISAV-B without following a biosimilar model.
International manufacturers, including Serum Institute of India and other large vaccine producers, could affect pricing and procurement in emerging markets. Their immediate impact on U.S. adult private-sector pricing is limited by FDA approval, manufacturing validation and contracting requirements.
What licensing deals support the HEPLISAV-B and CpG 1018 franchise?
Dynavax has pursued partnerships for CpG 1018 beyond HEPLISAV-B, including collaborations involving COVID-19 vaccines and other vaccine programs. These agreements have provided milestone, royalty and supply-related revenue, but they are less predictable than HEPLISAV-B sales. [1]
The strategic value of CpG 1018 licensing is twofold:
- It can monetize the adjuvant without requiring Dynavax to fund every vaccine development program.
- It can expand the platform through partners with global manufacturing, regulatory and distribution infrastructure.
The financial risk is that partner programs may terminate, delay or fail commercially. HEPLISAV-B remains the most important validated source of product revenue.
What generic launch scenarios exist for HEPLISAV-B?
Base case
HEPLISAV-B continues to gain adult share through pharmacy, occupational-health and health-system adoption. Revenue growth slows from launch-stage rates but remains positive as the two-dose schedule converts patients from legacy vaccines.
Downside case
Engerix-B and Recombivax HB use contracting and price discounts to defend share. Public-sector volume grows without equivalent net-price growth. Dynavax’s revenue rises slowly while manufacturing, sales and regulatory costs remain elevated.
Disruption case
A competitor introduces a two-dose or single-visit adult vaccine with equal or better seroprotection, broad age labeling and favorable procurement pricing. This would directly weaken HEPLISAV-B’s core differentiation.
Patent-entry case
A rival develops an independently approved CpG-containing or otherwise adjuvanted hepatitis B vaccine. The entrant does not need to be a biosimilar to pressure HEPLISAV-B. Patent litigation could delay entry, but clinical and manufacturing requirements would remain the principal barriers.
How does HEPLISAV-B compare with Engerix-B and Recombivax HB?
| Factor |
HEPLISAV-B |
Engerix-B |
Recombivax HB |
| Doses for typical adult course |
2 |
3 |
3 |
| Completion advantage |
High |
Lower because of longer schedule |
Lower because of longer schedule |
| Established pediatric use |
No |
Yes |
Yes |
| Adult immunogenicity differentiation |
Strong |
Established standard |
Established standard |
| Manufacturer scale |
Smaller specialist vaccine company |
Large global vaccine company |
Large pharmaceutical company |
| Contracting power |
More limited |
Strong |
Strong |
| Main commercial advantage |
Convenience and rapid completion |
Broad label and supply depth |
Broad familiarity and established contracts |
| Main commercial risk |
Product concentration and price pressure |
Slower completion |
Slower completion |
HEPLISAV-B has the better schedule. GSK and Merck have the broader franchises and greater procurement leverage.
What is the revenue exposure for investors and licensing partners?
HEPLISAV-B is Dynavax’s central recurring asset. Product revenue growth can improve cash generation and reduce dependence on external financing, but concentration risk remains high. The company’s financial performance is sensitive to:
- Adult vaccine volume.
- Average net selling price.
- Government and institutional discounts.
- Contract manufacturing and supply costs.
- Sales-force efficiency.
- Inventory and channel levels.
- Reimbursement changes.
- CpG 1018 partnership milestones and royalties.
For licensing partners, CpG 1018 offers platform exposure without acquiring the entire HEPLISAV-B commercial business. For investors, the key question is whether HEPLISAV-B can become a durable, cash-generating adult vaccine franchise before competitive or patent pressures intensify.
Key Takeaways
- HEPLISAV-B is Dynavax’s FDA-approved two-dose adult hepatitis B vaccine using CpG 1018.
- Its principal commercial advantage is faster schedule completion than Engerix-B and Recombivax HB.
- U.S. demand benefited from CDC universal adult vaccination recommendations and expanded pharmacy and health-system adoption.
- The product has become Dynavax’s primary recurring revenue source, while COVID-19-related CpG 1018 revenue is less predictable.
- Competitive risk is more likely to come from a new FDA-approved vaccine than from a conventional generic or biosimilar.
- Patent protection involves CpG 1018 compositions, vaccine combinations, methods of use and manufacturing-related claims.
- The main financial risk is concentration in one adult product and one major market.
- Long-term growth depends on continued adult market-share conversion, supply reliability, reimbursement and the absence of a superior two-dose or single-dose competitor.
FAQs
Is HEPLISAV-B a biosimilar?
No. HEPLISAV-B is a licensed recombinant vaccine, not a biosimilar version of another biologic. A competing hepatitis B vaccine would generally require its own FDA regulatory approval.
Can pharmacies automatically substitute HEPLISAV-B for Engerix-B?
Substitution rules depend on state law, payer policy and product-specific authorization. HEPLISAV-B and Engerix-B are not conventional interchangeable generic products.
Does HEPLISAV-B have a pediatric indication?
No. FDA approval covers adults aged 18 years and older. Pediatric hepatitis B demand is served mainly by established pediatric and combination vaccines.
What would most directly reduce HEPLISAV-B sales?
A competing vaccine with a comparable or shorter schedule, strong immunogenicity in older and immunocompromised adults, broad age labeling and lower contracted pricing would pose the most direct threat.
Is CpG 1018 commercially valuable outside hepatitis B vaccination?
Yes. CpG 1018 is a vaccine adjuvant platform that Dynavax has licensed or partnered for other vaccine programs. Its value outside HEPLISAV-B depends on partner development, regulatory approval, manufacturing scale and commercial uptake.
References
-
Dynavax Technologies Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Centers for Disease Control and Prevention. (2022). Universal hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 71(13), 477-483.
-
U.S. Food and Drug Administration. (2017). HEPLISAV-B prescribing information. Dynavax Technologies Corporation.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for Dynavax Technologies CpG immunostimulatory oligonucleotide and vaccine patent families.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
